Patent ID: 9155736
Filing Date: 2015-10-13
Classification: A61K,A61P,C12Q,G01N

Abstract:
1. A method for inhibiting phosphorylation of PRAS40, GSK3β or p70S6K1 in a biological sample of a patient having cancer, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof to said patient and comparing the amount of phosphorylated PRAS40, GSK3β or p70S6K1 in a blood, skin, tumor or circulating tumor cells in blood biological sample of a patient obtained prior to and after administration of said 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, wherein less phosphorylated PRAS40, GSK3β and/or p70S6K1 in said biological sample obtained after administration of said 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof relative to the amount of phosphorylated PRAS40, GSK3β and/or p70S6K1 in said biological sample obtained prior to administration of said 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof indicates inhibition, wherein the amount of phosphorylated PRAS40, GSK3β or p70S6K1 in said biological sample is measured using flow cytometry, ELISA, immunohistochemistry using phosphorylation-specific antibodies, western blotting, immunofluorescence or Luminex® technologies.